Comparative effectiveness research using NCCN data

使用 NCCN 数据进行比较有效性研究

基本信息

批准号：
7942775
负责人：
JANE C. WEEKS
金额：
$ 49.89万
依托单位：
DANA-FARBER CANCER INST
依托单位国家：
美国
项目类别：
财政年份：
2009
资助国家：
美国
起止时间：
2009-09-30 至 2012-08-31
项目状态：
已结题

来源：
https://reporter.nih.gov/project-details/7942775
关键词：
Accounting Address Advocate Agreement Area Cancer Center Cancer Patient Characteristics Clinical Colorectal Cancer Communities Community Practice Data Databases Development Disease Effectiveness Elderly Grant Institution Lead Left Malignant Neoplasms Malignant neoplasm of lung Medicaid National Cancer Institute National Comprehensive Cancer Network Non-Hodgkin&apos s Lymphoma Observational Study Outcome Outcome and Process Assessment Patient Care Patients Peer Review Policy Maker Process Public Health Research Research Personnel Resources Subgroup System Treatment outcome United States United States Centers for Medicare and Medicaid Services Variant Work alternative treatment base cancer diagnosis cancer therapy comparative effectiveness cost effective therapy effectiveness research evidence base improved malignant breast neoplasm member oncology tumor

项目摘要

DESCRIPTION (provided by applicant): This application addresses broad Challenge Area (05) Comparative Effectiveness Research and specific Challenge Topic, 05-CA-104*: Comparative Effectiveness Research on Cancer Treatment. We propose to address two distinct but related challenges: (1) development of a research agenda for cancer comparative effectiveness research (CCER) that takes into account both the feasibility of the research and its potential importance to relevant stakeholders; and (2) completion of several high priority and high quality assessments of the comparative effectiveness of alternative cancer treatments for specific clinical subsets of cancer patients. We will use a unique data resource that we have assembled over the past 12 years that is ideally suited to CCER and that makes it feasible to complete this ambitious scope of work within the grant period. The National Comprehensive Cancer Network (NCCN), an affiliation of 21 of the leading cancer centers in the United States, has been collecting detailed baseline, treatment, and outcome data on patients treated in member institutions since 1997. Using data from the NCCN Breast Cancer, Lung Cancer, Colorectal Cancer, and Non-Hodgkin's Lymphoma Outcomes Databases we propose to: Aim 1. Develop a set of candidate targets for cancer comparativeness effectiveness research by identifying specific treatment decisions for which there is an incomplete or non-existent evidence base and observed practice variation unrelated to patient characteristics. Aim 2. Prioritize these treatment decisions for CCER based on input from key stakeholders including the National Cancer Institute, the Centers for Medicare and Medicaid Services, state Medicaid plans, major private payers, patient advocates, and the oncology practice community. Aim 3. Conduct assessments of process-outcome linkage for 4 treatment decisions identified as high priority topics for CCER using data from the NCCN Outcomes Databases. This project will provide policy-makers and the research community with an empirically-based and systematic prioritization of research topics, thus increasing both the efficiency and the public health impact of the comparative effectiveness research enterprise. And by selecting 4 high priority topics for analysis using the clinically detailed data available in the NCCN Outcomes database, we anticipate that our findings can help to define and lead to more effective treatment for thousands or even millions of cancer patients in the near term. -- Relevance The four diseases we're proposing to study represent 48% of all cancer diagnoses in the United States. We are proposing to take a systematic approach to identifying aspects of care for these patients that may be suboptimal, and then conducting research that will identify how the effectiveness of their treatment could be improved.

说明（由申请人提供）：本申请涉及广泛的挑战领域 (05) 比较有效性研究和具体挑战主题 05-CA-104*：癌症治疗的比较有效性研究。我们建议解决两个不同但相关的挑战：（1）制定癌症比较有效性研究（CCER）的研究议程，考虑到研究的可行性及其对相关利益相关者的潜在重要性； (2) 完成多项高优先级和高质量的评估，评估替代癌症治疗对特定临床癌症患者亚群的比较有效性。我们将使用我们在过去 12 年中收集的独特数据资源，该资源非常适合 CCER，并且可以在资助期内完成这一雄心勃勃的工作范围。国家综合癌症网络 (NCCN) 是美国 21 个领先癌症中心的附属机构，自 1997 年以来一直在收集在成员机构接受治疗的患者的详细基线、治疗和结果数据。使用来自 NCCN 乳腺癌的数据、肺癌、结直肠癌和非霍奇金淋巴瘤结果数据库，我们建议：目标 1. 通过确定以下癌症的具体治疗决策，制定一套癌症比较有效性研究的候选目标：其中存在不完整或不存在的证据基础，并且观察到与患者特征无关的实践变化。目标 2. 根据主要利益相关者（包括国家癌症研究所、医疗保险和医疗补助服务中心、州医疗补助计划、主要私人付款人、患者权益倡导者和肿瘤学实践社区）的意见，优先考虑 CCER 的这些治疗决策。目标 3. 使用 NCCN 结果数据库中的数据，对被确定为 CCER 高度优先主题的 4 个治疗决策的过程-结果联系进行评估。该项目将为政策制定者和研究界提供基于经验的、系统的研究主题优先顺序，从而提高比较有效性研究企业的效率和对公共卫生的影响。通过使用 NCCN 结果数据库中提供的临床详细数据选择 4 个高度优先的主题进行分析，我们预计我们的研究结果将有助于在短期内为数千甚至数百万癌症患者定义并带来更有效的治疗。 -- 相关性我们建议研究的四种疾病占美国所有癌症诊断的 48%。我们建议采取系统的方法来确定这些患者的护理可能不理想的方面，然后进行研究以确定如何提高治疗的有效性。